1-4 of 4
Merrill Egorin
Close
Sort by
Journal Articles

A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.

Tapan M. Kadia, MD, Alessandra Ferrajoli, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Deborah Thomas, MD, William Wierda, MD, PhD, Srdan Verstovsek, MD, Willie Newsome, James Zwiebel, MD, Merrill Egorin, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2007) 110 (11): 1842.
https://doi.org/10.1182/blood.V110.11.1842.1842
Published: 2007
Journal Articles

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Carolyn Blasdel, MA, RN, FNP, Yanfeng Wang, PhD, Theodore Lagattuta, BS, Brian Druker, MD, Laurie Letvak, MD, Merrill Egorin, MD FACP
Journal: Blood
Blood (2006) 108 (11): 4820.
https://doi.org/10.1182/blood.V108.11.4820.4820
Published: 2006
Journal Articles

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.

Steven Grant, Judith E. Karp, Omer N. Koc, Brenda Cooper, Selina Luger, William D. Figg, Merrill Egorin, Brian J. Druker, James W. Jacobberger, Viswanathan Ramakrishnan, Edward B. Perkins, A. Dimitrios Colevas, John D. Roberts
Journal: Blood
Blood (2005) 106 (11): 1102.
https://doi.org/10.1182/blood.V106.11.1102.1102
Published: 2005
Journal Articles

The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia

Brief Report
Nicholas C. Wolff, James A. Richardson, Merrill Egorin, Robert L. Ilaria, Jr
Journal: Blood
Blood (2003) 101 (12): 5010–5013.
https://doi.org/10.1182/blood-2002-10-3059
Published: 2003